Viewing data from:

POTASSIUM CITRATE

ANDA

POTASSIUM CITRATE | A214420 | ASCENT PHARMACEUTICALS INC

3 strengths0 unique patents0 unique exclusivities

Reference Listed Drug: UROCIT-K(TE code: AB)

Drug Pricing (NADAC)

National Average Drug Acquisition Cost — Week of 2026-07-15 | 3 NDCs

Highest NADAC/Unit

$0.1813

per ea

Lowest NADAC/Unit

$0.1348

per ea

Brand NDCs

Generic NDCs

NDC Description	NADAC/Unit	Unit	Type	Generic NADAC	Effective
31722013001POTASSIUM CITRATE ER 10 MEQ TB	$0.1813	EA	Generic	—	2026-06-17
31722013201POTASSIUM CITRATE ER 15 MEQ TB	$0.1796	EA	Generic	—	2026-06-17
31722012901POTASSIUM CITRATE ER 5 MEQ TAB	$0.1348	EA	Generic	—	2026-06-17

Source: NADAC (data.medicaid.gov). Prices reflect national average acquisition costs for retail community pharmacies.

VA Federal Supply Schedule

Government-negotiated contract prices | 3 NDCs (3 FSS)

Lowest Price

$21.50

Highest Price

$98.99

FSS NDCs

Big4 NDCs

Description	Price	Type	Vendor	Contract End
72865-0191-01POTASSIUM CITRATE 5MEQ TAB,SA	$21.50	FSS	XLCare Pharmaceuticals, Inc.	05/31/2026
72865-0192-01POTASSIUM CITRATE 10MEQ TAB,SA	$48.00	FSS	XLCare Pharmaceuticals, Inc.	05/31/2026
72865-0193-01POTASSIUM CITRATE 15MEQ TAB,SA	$98.99	FSS	XLCare Pharmaceuticals, Inc.	05/31/2026

Source: VA Federal Supply Schedule (va.gov). Prices are government-negotiated contract prices.

API Supply Chain2 active DMFs1 inactive

2 active API suppliers hold Drug Master Files for this ingredient. Limited supplier base — potential supply chain risk.

TAPI NL BVPOTASSIUM CITRATE USP

DMF 310682016

GLOBAL CALCIUM PRIVATE LTDPOTASSIUM CITRATE USP

DMF 368752022

ARCHER DANIELS MIDLAND COInactivePOTASSIUM CITRATE MONOHYDRATE

DMF 103011993

Source: FDA Drug Master Files (fda.gov). Type II API DMFs matched by ingredient.

Products (3)

Sort:

#001 — 5MEQ

0 patents0 exclusivities▴

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 5, 2021

No patent or exclusivity listings for this strength.

#002 — 10MEQ

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 5, 2021

#003 — 15MEQ

0 patents0 exclusivities▾

TABLET, EXTENDED RELEASE;ORAL | Approved: Feb 5, 2021